Gastrointestinal dysfunction is common in Parkinson's disease. Fiber therapy could be used to reduce the symptoms of gastrointestinal motility disorders. In a previous study, we showed that slowed gastrointestinal motility modified levodopa pharmacokinetics: area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C(max)) decreased and the elimination was delayed. In this study, we evaluated whether or not the hydrosoluble fiber Plantago ovata husk is useful in improving levodopa pharmacokinetics in rabbits with autonomic gastrointestinal disorders induced by the administration of the anticholinergic biperiden. Levodopa + carbidopa (20:5 mg/kg), biperiden (100 microg/kg), and P. ovata husk (at two different doses: 100 and 400 mg/kg) were administered orally to rabbits for two periods of time (7 or 14 days). In all groups of animals, the AUC values were approximately 50% higher on the final day of treatment than on day 1. C(max) was also higher, with the greater increase at the 400 mg/kg dose of fiber, which resulted in a boost of approximately 35%. On day 1 of treatment and with both doses of fiber, AUC values were very similar to those obtained in previous work in rabbits with normal gastrointestinal motility, but the C(max) was lower. However, after 7 or 14 days, the AUC values were higher, but C(max) remained lower. The greatest differences were observed in plasma concentration before drug administration (C(min)), for which the highest increase was obtained with the dose of 400 mg/kg fiber on day 14 of treatment (349.8%). P. ovata husk could be beneficial in patients with Parkinson's disease because it regulates stool transit in the intestine and because it improves levodopa pharmacokinetics when gastrointestinal peristalsis is slowed. These changes could lead to a possible delay in the onset of dyskinesias and to changes in prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.108.026229DOI Listing

Publication Analysis

Top Keywords

ovata husk
16
gastrointestinal motility
12
levodopa pharmacokinetics
12
400 mg/kg
12
auc values
12
day treatment
12
plantago ovata
8
levodopa carbidopa
8
rabbits autonomic
8
autonomic gastrointestinal
8

Similar Publications

is a common medicinal plant widely cultivated in tropical regions of the world. The outer seed coat of , obtained by cleaning the seeds, contains soluble and insoluble fibre in a ratio of 7:3, making products containing husk an ideal source of health-beneficial fibre. The results of clinical trials demonstrate the therapeutic efficacy of psyllium husk for various gastrointestinal disorders.

View Article and Find Full Text PDF

A tablet is a compact dosage form that includes both the active pharmaceutical ingredient (API) and various excipients, where a binder acts as an excipient, imparting cohesive quality in the powdered material. The present study aimed to extract polysaccharides from plant samples; Plantago ovata seeds, Plantago ovata husk, Lallemantia royleana, Ocimum basilicum and Acacia nilotica and to investigate their efficacy as tablet excipients. The wet granulation method was adopted for tablet formulation.

View Article and Find Full Text PDF

The aim of the study was to determine the influence of the different shares (0/100, 5/95, 10/90 and 15/85 ratios) of a ground psyllium fiber (PF) mixture of 80% psyllium seeds () and 20% psyllium husk () on the quality characteristics, chemical composition, total polyphenolic content (TPC), and antioxidant activity of rye bread (RB). The study was conducted with rye flour (RF) type 580 and 720 and two dough preparation methods (single-phase-1F, two-phase-2F). The inclusion of psyllium fiber in rye bread resulted in an increase in the overbaking of bread by 12.

View Article and Find Full Text PDF

Micronized oat husk and Plantago ovata husk were used as dietary fiber sources in wheat bread. The addition of 20% micronized oat husk improved dough yield but resulted in a darker bread crumb, decreased loaf volume, and deteriorated texture. In contrast, 5% P.

View Article and Find Full Text PDF

Chronic kidney disease (CKD) can cause gut microbiota dysbiosis and thus impair intestinal barrier function. Disruption of intestinal homeostasis facilitates the production of enterogenic toxins, which exacerbate CKD-induced uremic toxicity and inflammation. Dietary fiber, by targeting the gut-kidney axis, could be used for CKD treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!